Blog - Page 3280 of 5757

WednesdayMay 09, 2012 3:52 pm

ImmunoCellular Therapeutics Ltd. (IMUC) Updates on Clinical Activity and Patient Enrollment for Study of Brain Cancer Vaccine Candidate

ImmunoCellular Therapeutics, a biotech company focused on the development of novel immune-based cancer therapies, today issued an update on clinical trial site activity and patient enrollment for its phase II clinical trial of ICT-107, the company's cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM), the most aggressive malignant primary brain tumor. The company reports that it has initiated the trial in 25 sites, and that it expects to enroll approximately 200 or more patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There currently are 189 patients enrolled in the study, with final enrollment…

WednesdayMay 09, 2012 1:42 pm

Complete Genomics (GNOM) Sequences Genomes in Type 2 Diabetes Genetic Study

Complete Genomics Inc. is whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing service. The company's Complete Genomics Analysis Platform combines its proprietary human genome sequencing technology with advanced informatics and data management software. The company today announced that it has sequenced the genomes of 600 individuals from 20 Mexican-American from San Antonio, Texas. This is thought to be the largest whole genome sequencing family study conducted to date and the first such study of its kind in an Hispanic population. The study was funded by the National Institute of Diabetes and Digestive and Kidney…

WednesdayMay 09, 2012 9:37 am

THQ Inc. (THQI) Video Chart for Wednesday, May 9, 2012

After hitting a 45 cent low last month, THQI made a strong move to hit 79 cents. A retracement has seen the stock go down to a support level around 65 cents, which may help the chart find a bottom. The support level must hold or the potential of falling back down to 45 cents is greatly increased. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts Let us hear your thoughts below:

WednesdayMay 09, 2012 8:58 am

Skinny Nutritional Corp. (SKNY) is “One to Watch”

Skinny Nutritional has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water’s proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water. With a wide selection of eight different great tastes to choose from, each designed for a specific function, like Hi-Energy - Acai Grape Blueberry (super charged with B vitamins and…

WednesdayMay 09, 2012 8:57 am

Houston American Energy (HUSA) Closes on Registered Equity Offering

Houston American Energy issued an update to investors on the company’s recent financial and oil and gas operational activity in the United States. Houston American Energy has closed on a direct offering of the company’s common stock to a group of institutional investors. The company sold 6.2 million units at $2.12 per unit, raising gross proceeds of $13.1 million. Houston American Energy reported that each unit consisted of one share of the company’s common stock and one stock purchase warrant. The warrant gives the holder the right to acquire one share of Houston American Energy common stock at an exercise…

WednesdayMay 09, 2012 8:45 am

Rexahn Pharmaceuticals, Inc. (RNN) Submits Phase II Protocol to FDA for Clinical Study of Archexin as Treatment for Ovarian Cancer

Yesterday, clinical stage pharmaceutical company Rexahn Pharmaceuticals, Inc. announced it has submitted a phase II protocol to the U.S. Food and Drug Administration for the clinical study of Archexin(R) as a treatment for ovarian cancer. Archexin is a first-in-class Akt protein kinase inhibitor that has the potential utility to inhibit cancer cell survival and proliferation, angiogenesis, and drug resistance. Based on data from the phase I clinical trial, Archexin has an excellent human safety profile, with fatigue as its only side-effect. Archexin has received FDA Orphan drug designation for five difference cancer types, including renal cell carcinoma, glioblastoma and pancreatic,…

TuesdayMay 08, 2012 5:31 pm

ProGaming Platforms Corp. (PPTF) Global Market Approach

ProGaming Platforms, Israel-based designer of one of the world’s most advanced multi-player online gaming and reward processing platforms, has a clearly developed plan for its entry into the fast-growing global gaming marketplace. Their product is game-independent, a proprietary online gaming and associated billing platform that allows gamers anywhere in the world to compete with one another in games of skill, with as few or as many players as wanted, keeping accurate track of all players and scores, with the winner collecting the winning money or other rewards. A key differentiator is the system’s automatic accounting process, unmatched in the marketplace.…

TuesdayMay 08, 2012 4:08 pm

Infrax Systems, Inc. (IFXY) Introduces SPIDer Detection and Identification Network

Infrax Systems provides unified Smart Grid-related products and services for the energy and utility industries. The company today launched its SPIDer (Secure Perimeter Intrusion Detection) network designed to address the threats of copper theft and malicious attacks on power substations, generation facilities, and critical infrastructure in the electric utility industry. The Department of Energy reports that copper theft, site destruction, and malicious activity generate theft-related costs up to $1 billion nationwide. However, the DoE reports that costs due to the actual theft of the copper are very small compared to the costs to repair the damage to the equipment and…

TuesdayMay 08, 2012 3:23 pm

Zynex, Inc. (ZYXI) Posts Q1 Preliminary Results Lifted by Subsidiary Strength

Zynex, a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis, and cardiac monitoring, today posted its first quarter 2012 unaudited financial results. The company's total first-quarter net revenue increased 35 percent to $8.9 million compared to $6.6 million reported for the first quarter of the year prior. The company attributes the increase in sales to its Zynex Medical subsidiary, in which strong demand continues from its products. A small amount of revenue was derived from its Zynex NeuroDiagnostics subsidiary. First quarter 2012 net income was $320,000, or $0.01 per share, versus a net loss…

TuesdayMay 08, 2012 3:21 pm

Quasar Aerospace Industries, Inc. (QASP) Announces Management Change, CATS Application Approval, and Conference Call Rescheduling

Quasar Aerospace Industries made several announcements today concerning a management change, the acceptance of its CATS (Computer Assisted Testing Service) application, and the rescheduling of a previously announced conference call. Mr. William F. “Bill” Cirmo II has been nominated to fill the void as Chief Operating Officer and would be responsible for overseeing flight training and ground operations for subsidiaries. Mr. Henderson is no longer with the corporation and, in accordance with his employment agreement, has resigned from all positions in Quasar and its subsidiaries. Bill Cirmo began his distinguished career in aviation as an aviator for the US Navy,…

Site Search

Company Search